Abstract
Data on the effects of synbiotic supplementation on glycemic control, lipid profiles, and atherogenic index of plasma (AIP) of women with polycystic ovary syndrome (PCOS) are limited. The purpose of this study was to assess the effects of synbiotic supplementation on glycemic control and lipid profiles in women with PCOS. A prospective, randomized, double-blind, placebo-controlled trial was done at the Naghavi Hospital affiliated to Kashan University of Medical Sciences, Kashan, Iran, between April 2017 and June 2017. Sixty women with PCOS were randomized to intake synbiotic capsule containing Lactobacillus acidophilus strain T16 (IBRC-M10785), Lactobacillus casei strain T2 (IBRC-M10783), and Bifidobacterium bifidum strain T1 (IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to determine related variables. Compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum insulin concentrations (− 2.8 ± 4.1 vs. + 1.8 ± 6.4 μIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (− 0.7 ± 1.0 vs. + 0.4 ± 1.5, P = 0.002), and a significant elevation in the quantitative insulin sensitivity check index (+ 0.01 ± 0.01 vs. − 0.01 ± 0.03, P < 0.001). In addition, significant decreases in serum triglycerides (− 16.2 ± 31.4 vs. + 5.8 ± 23.1 mg/dL, P = 0.003), VLDL-cholesterol concentrations (− 3.3 ± 6.3 vs. + 1.1 ± 4.6 mg/dL, P = 0.003), and AIP (− 0.05 ± 0.08 vs. − 0.003 ± 0.10 mg/dL, P = 0.03) were seen following the supplementation of synbiotic compared with the placebo. Overall, we found that synbiotic supplementation to women with PCOS for 12 weeks had beneficial effects on markers of insulin resistance, triglycerides, VLDL-cholesterol concentrations, and AIP, but did not influence other lipid profiles. Trial registration: www.irct.ir: IRCT201604015623N71.
Similar content being viewed by others
Change history
08 September 2020
Editor's Note: The Editor-in-Chief is currently investigating this article as concerns have been raised about integrity of the clinical trial reported here. There is also an ongoing investigation by the Iranian National Committee for Ethics in Biomedical Researches. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Abbreviations
- AIP:
-
Atherogenic index of plasma
- PCOS:
-
Polycystic ovary syndrome
- VLDL:
-
Very-low-density lipoprotein
- CFU:
-
Colony forming units
- T2DM:
-
Type 2 diabetes mellitus
- CVD:
-
Cardiovascular diseases
- GDM:
-
Gestational diabetes mellitus
- FPG:
-
Fasting plasma glucose
- METs:
-
Metabolic equivalents
- CVs:
-
Coefficient variances
- HOMA-IR:
-
Homeostatic model of assessment for insulin resistance
- QUICKI:
-
Quantitative insulin sensitivity check index
- SCFA:
-
Short-chain fatty acids
- NF-κB:
-
Nuclear factor-kappaB
References
Witchel SF, Roumimper H, Oberfield S (2016) Polycystic ovary syndrome in adolescents. Endocrinol Metab Clin N Am 45:329–344
Nandi A, Chen Z, Patel R, Poretsky L (2014) Polycystic ovary syndrome. Endocrinol Metab Clin N Am 43:123–147
Musso G, Gambino R, Cassader M (2010) Obesity, diabetes, and gut microbiota. Diabetes Care 33:2277–2284
Sharif A, Kashani HH, Nasri E, Soleimani Z, Sharif MR (2017) The role of probiotics in the treatment of dysentery: a randomized double-blind clinical trial. Probiotics Antimicrob Proteins 9(4):380–385
Sharif MR, Kashani HH, Ardakani AT, Kheirkhah D, Tabatabaei F, Sharif A (2016) The effect of a yeast probiotic on acute diarrhea in children. Probiot Antimicrob Proteins 8:211–214
Neis EP, Dejong CH, Rensen SS (2015) The role of microbial amino acid metabolism in host metabolism. Nutrients 7:2930–2946
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R (2002) Obesity and the polycystic ovary syndrome. Int J Obes 26:883–896
Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, Tang L (2016) Association between polycystic ovary syndrome and gut microbiota. PLoS One 11:e0153196
Jung S-P, Lee K-M, Kang J-H, Yun S-I, Park H-O, Moon Y, Kim J-Y (2013) Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 34:80–89
Lee SJ, Bose S, Seo J-G, Chung W-S, Lim C-Y, Kim H (2014) The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: a randomized double-blind controlled clinical trial. Clin Nutr 33:973–981
Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A (2016) Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci 17:928
Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S (2012) Host-gut microbiota metabolic interactions. Science 336:1262–1267
Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, Memarzadeh MR, Asemi Z (2017) Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb):1–8
Mikelsaar M, Sepp E, Štšepetova J, Hütt P, Zilmer K, Kullisaar T, Zilmer M (2015) Regulation of plasma lipid profile by Lactobacillus fermentum (probiotic strain ME-3 DSM14241) in a randomised controlled trial of clinically healthy adults. BMC Nutr 1:27
Shoaei T, Heidari-Beni M, Tehrani HG, Feizi A, Esmaillzadeh A, Askari G (2015) Effects of probiotic supplementation on pancreatic beta-cell function and C-reactive protein in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Int J Prev Med 6:27. https://doi.org/10.4103/2008-7802.153866
Eshre TR, Group, A.-S.P.C.W (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
Ogden CL, Carroll MD, Flegal KM (2008) High body mass index for age among US children and adolescents, 2003–2006. JAMA 299:2401–2405
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, Dadgarmoghaddam M (2015) Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran 29:240
Hadaegh F, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F (2009) Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis 19:401–408
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou Z-G, Liu F, Wong RL, Chow W-S, Tso AW, Lam KS (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246–1253
Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT (2013) Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 36:845–853
Taghizadeh M, Asemi Z (2014) Effects of synbiotic food consumption on glycemic status and serum hs-CRP in pregnant women: a randomized controlled clinical trial. Hormones (Athens) 13:398–406
Bargiota A, Diamanti-Kandarakis E (2012) The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 3:27–47
Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91:435–442
Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY (2016) Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr 56(4):1535–1550
Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A (2013) Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 63:1–9
Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, Jakobsen M, Pedersen BK (2010) Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 104:1831–1838
Fernandes R, do Rosario VA, Mocellin MC, Kuntz MG, Trindade EB (2016) Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: a systematic review. Clin Nutr 36(5):1197–1206
Nitert MD, Barrett HL, Foxcroft K, Tremellen A, Wilkinson S, Lingwood B, Tobin JM, McSweeney C, O’Rourke P, McIntyre HD (2013) Spring: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women. BMC Pregnancy Childbirth 13:50
Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Kakhaki RD, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z (2016) Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr 36(5):1245–1249
Macut D, Bozic-Antic I, Bjekic-Macut J, Tziomalos K (2017) Management of endocrine disease: polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol 177:R145–R158
Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106:131–137
Malaguarnera M, Vacante M, Bertino G, Neri S, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G et al (2011) The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interf Cytokine Res 31:653–659
Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Carteni M, Nardone G (2012) Gut-liver axis: the impact of gut microbiota on nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22:471–476
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343–350
Letexier D, Diraison F, Beylot M (2003) Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77:559–564
Tabrizi R, Moosazadeh M, Lankarani KB, Akbari M, Heydari ST, Kolahdooz F, Asemi Z (2017) The effects of synbiotic supplementation on glucose metabolism and lipid profiles in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Probiot Antimicrob Proteins:1–14
Kullisaar T, Shepetova J, Zilmer K, Songisepp E, Rehema A, Mikelsaar M, Zilmer M (2011) An antioxidant probiotic reduces postprandial lipemia and oxidative stress. Open Life Sci 6:32–40
Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y, Asemi Z (2014) Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 49:695–701
Schaafsma G, Meuling WJ, van Dokkum W, Bouley C (1998) Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers. Eur J Clin Nutr 52:436–440
Wild RA (2012) Dyslipidemia in PCOS. Steroids 77:295–299
Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO (2012) Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 18:112–126
Matsuoka H, Miura A, Hori K (2009) Symbiotic effects of a lipase-secreting bacterium, Burkholderia arboris SL1B1, and a glycerol-assimilating yeast, Candida cylindracea SL1B2, on triacylglycerol degradation. J Biosci Bioeng 107:401–408
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015–3025
Yadav H, Lee JH, Lloyd J, Walter P, Rane SG (2013) Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288:25088–25097
Acknowledgments
The present study was supported by a grant from the Vice-chancellor for Research, Kashan University of Medical Sciences, Kashan, Iran.
Funding
No funding has been received.
Author information
Authors and Affiliations
Contributions
ZA contributed in the conception, design, statistical analysis, and drafting of the manuscript. MS, AD, HH-K, ESH, and MT-E contributed in the data collection and manuscript drafting. Z.A. supervised the study.
Corresponding author
Ethics declarations
Ethical Responsibilities of Authors
This paper is our original unpublished work and it has not been submitted to any other journal for reviews.
Availability of Data and Materials
The primary data for this study is available from the authors on direct request.
Ethics Approval and Consent to Participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.
Consent for Publication
Not applicable.
Competing Interests
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Samimi, M., Dadkhah, A., Haddad Kashani, H. et al. The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. Probiotics & Antimicro. Prot. 11, 1355–1361 (2019). https://doi.org/10.1007/s12602-018-9405-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12602-018-9405-z